Investors

Press Releases

Press Releases

Press Releases

September 14, 2020
Collegium Announces Five Posters Presented at PAINWeek 2020 National Conference
STOUGHTON, Mass. , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that five poster presentations highlighting data regarding its product portfolio were
August 5, 2020
Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020
– Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020 – – Generated $43.9 Million in Cash from Operating Activities in the Second Quarter of 2020 – – Xtampza   ® ER Net Revenue Increased 29% over the Prior Year Period – – Conference Call Scheduled for Today at 4:30 p.m.
May 7, 2020
Collegium Reports First Quarter 2020 Profitability
– Achieves GAAP Profitability with $0.5 Million in Net Income in the First Quarter of 2020 – – Non-GAAP Net Income of $31.2 Million in the First Quarter of 2020 – – Xtampza ® ER Prescriptions Grew 30% Over the First Quarter of 2019 – – Collegium Updates 2020 Guidance to Reflect COVID-19 Impact – –
April 7, 2020
Collegium to Participate in Upcoming Investor Conference
STOUGHTON, Mass. , April 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference in April: The
February 27, 2020
Collegium Reports Full-Year 2019 Revenue of $296.7 Million
– 2019 Revenue Growth of 6%, Driven by Xtampza ER revenue growth of 51% – – Xtampza ® ER Prescriptions Grew 49% in 2019 – – Collegium Guides to Profitability in 2020 – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. , Feb. 27, 2020 (GLOBE NEWSWIRE) --   Collegium
February 13, 2020
Collegium Announces Closing of the Nucynta Franchise Acquisition
– Collegium Announces Closing of Convertible Senior Notes Offering and Exercise in Full of Over-Allotment Option – – Collegium will Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and Provide Corporate Update – STOUGHTON, Mass. , Feb.
February 6, 2020
Collegium to Acquire U.S. Rights to Nucynta Franchise
– Financially Transformative Acquisition – – Expected to Significantly Grow Net Income, EBITDA and Operating Cash Flows – – Structure of the Financing Allows for Rapid De-Leveraging – – Provides Financial Flexibility to Pursue Future Business Development Transactions – STOUGHTON, Mass. , Feb.
January 7, 2020
Collegium Provides 2020 Financial Guidance
– Xtampza ® ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020 – STOUGHTON, Mass. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today